Clinical Trials Logo

Filter by:
NCT ID: NCT00800592 Completed - Clinical trials for Hypertension, Pulmonary

Sildenafil IV Bolus Study

Start date: October 2008
Phase: Phase 1
Study type: Interventional

The objective of this study is to assess the safety, tolerability and pharmacokinetics of intravenous sildenafil (10 mg) administered as a bolus injection to patients with Pulmonary Arterial Hypertension already receiving and stable on oral Revatio 20 mg TID.

NCT ID: NCT00800501 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis

Start date: December 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This study is conducted to evaluate the safety and tolerability of the drug product sNN0029, containing the growth factor VEGF165, when administered directly into one of the fluid filled cavities in the brain using an implanted catheter and an implanted SynchroMed® II pump. Patients with Amyotrophic Lateral Sclerosis will be enrolled.

NCT ID: NCT00799903 Completed - Atherosclerosis Clinical Trials

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

STABILITY
Start date: December 2008
Phase: Phase 3
Study type: Interventional

This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or stroke) in people with coronary heart disease.

NCT ID: NCT00798434 Completed - Clinical trials for Urinary Bladder, Overactive

A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.

SOFIA
Start date: June 2008
Phase: Phase 4
Study type: Interventional

The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment. It is postulated that this drug will also prove effective in elderly patients (aged > 65 years) and that the ability to change dose between 4 and 8mg will allow each patient to have an optimised treatment.

NCT ID: NCT00798369 Completed - Acute Gout Clinical Trials

Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients

Start date: November 2008
Phase: Phase 2
Study type: Interventional

This 8-week study is designed to determine the target dose of canakinumab (ACZ885) for the management of acute flare in gout patients who are contraindicated to Non-Steroidal anti-inflammatory drugs and/or colchicine. The efficacy of ACZ885 will be compared to the corticosteroid triamcinolone acetonide.

NCT ID: NCT00798317 Completed - Clinical trials for Vitreomacular Adhesion

Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.

Start date: December 2008
Phase: Phase 3
Study type: Interventional

This trial will evaluate the safety and efficacy of microplasmin, administered as an intravitreal injection, in subjects with focal vitreomacular adhesion. In previously performed clinical trials, some patients treated with intravitreal microplasmin have had resolution of their underlying condition, including macular hole closure, without need for vitrectomy. This clinical trial is justified because the sponsor believes the potential benefits outweigh the potential risks.

NCT ID: NCT00797641 Completed - Clinical trials for Gastrointestinal Hemorrhage

European Survey of Non-Variceal Upper Gastro Intestinal Bleeding (NVUGIB)

ENERGIB
Start date: January 2009
Phase: N/A
Study type: Observational

The aim of this study is to assess the current management strategies in a pan-European "real-life" setting to uncover the unmet need in this area: non-variceal gastrointestinal bleedings.

NCT ID: NCT00797342 Completed - Healthy Volunteers Clinical Trials

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04629991 in Healthy Volunteers

Start date: December 2008
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-04629991 in healthy subjects. Dose exploration will proceed in a step-wise manner, beginning with low doses not expected to have significant biological effects and proceeding to doses approximating or exceeding the anticipated therapeutic level. Doses to be explored may be limited by tolerability, and will not exceed levels previously shown to be tolerable in animals.

NCT ID: NCT00796614 Completed - Bladder, Neurogenic Clinical Trials

Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder

Start date: January 2008
Phase: Phase 2/Phase 3
Study type: Interventional

Aim of this study is to evaluate the efficacy and safety of a range of doses of tamsulosin hydrochloride as treatment in children with an elevated detrusor leak point pressure associated with a known neurological deficit

NCT ID: NCT00792753 Completed - Clinical trials for Coronary Artery Disease

Elixir Medical Clinical Evaluation of the Novolimus-Eluting Coronary Stent System: A Randomized Study "EXCELLA II STUDY"

Start date: October 2008
Phase: N/A
Study type: Interventional

Randomized Study To evaluate the safety and effectiveness of the Elixir Medical DESyne Novolimus-Eluting Coronary Stent System with Durable Polymer through the assessment of clinical, angiographic and IVUS endpoints as compared to the concurrently enrolled Medtronic Zotarolimus-Eluting Coronary Stent System in a randomized, single blind study of up to 200 male and female patients. In a Continued Access Registry of up to 100 patients receiving the DESyne Stent clinical-only endpoints will be evaluated. To evaluate the safety and effectiveness of the Elixir Novolimus-Eluting Coronary Stent System with bioabsorbable polymer as compared to the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System control through clinical and angiographic endpoints.